View in EDS PDF Full Text

Neuroendocrine predictors of response to intravenous clomipramine therapy for refractory obsessive–compulsive disorder Presented in part at the 2000 APA meeting May, Chicago, Illinois, Young Investigators Poster, and the 2001 ADAA Conference in Atlanta, Georgia

Saved in:
Bibliographic Details
Title: Neuroendocrine predictors of response to intravenous clomipramine therapy for refractory obsessive–compulsive disorder Presented in part at the 2000 APA meeting May, Chicago, Illinois, Young Investigators Poster, and the 2001 ADAA Conference in Atlanta, Georgia
Authors: Mathew, Sanjay J., Coplan, Jeremy D., Perko, Kathryn A., Goetz, Raymond R., De la Neuz, Manuel, Hollander, Eric, Liebowitz, Michael R., Fallon, Brian A., Mathew, S J (AUTHOR), Coplan, J D (AUTHOR), Perko, K A (AUTHOR), Goetz, R R (AUTHOR), de la Neuz, M (AUTHOR), Hollander, E (AUTHOR), Liebowitz, M R (AUTHOR), Fallon, B A (AUTHOR)
Source: Depression & Anxiety (1091-4269). 2001, Vol. 14 Issue 4, p199-208. 10p.
Subjects: Therapeutics, Obsessive-compulsive disorder, Neuroses, Pharmacology, Neuroendocrinology, Diagnosis of obsessive-compulsive disorder, Evaluation research, Research funding, Blind experiment, Drug administration, Hydrocortisone, Clomipramine, Treatment effectiveness, Oral drug administration, Prolactin, Intravenous therapy, Dose-effect relationship in pharmacology, Research methodology, Research, Treatment failure, Comparative studies, Human growth hormone
Abstract: The current study examines the neuroendocrine response to intravenous clomipramine (IV CMI) in oral CMI-resistant obsessive-compulsive disorder (OCD) patients on day 1 and day 14 of treatment to identify predictors of response. Forty-four OCD patients with an inadequate response or poorly tolerant to oral CMI were begun at 25 mg IV CMI, increasing to 250 mg by day 10, and continuing on that dose to day 14. On day 1, plasma levels of prolactin (PRL), growth hormone (GH), and cortisol were obtained immediately before the 25 mg IV infusion, and at five 30-minute time points after the infusion. On day 14, hormonal samples were obtained in a similar fashion. Response was assessed by the Clinical Global Impressions (CGI). Low PRL(MAX) to IV CMI and low cortisol levels overall on day 1 were both significantly associated with clinical response at day 14. An overall increase in growth hormone (GH) secretion during the day 14 testing was associated with positive response. A pronounced PRL response to IV CMI on day 14 was exhibited by the nonresponders, whereas a smaller and later but significant increase in PRL was noted in the responders. The findings suggest that in this sample of oral CMI-resistant patients with OCD, neuroendocrine measures derived from pharmacological challenge with IV CMI are capable of distinguishing IV CMI treatment responders from nonresponders. The limitations of IV CMI as a specific probe of serotonin function are discussed. [ABSTRACT FROM AUTHOR]
Copyright of Depression & Anxiety (1091-4269) is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
FullText Links:
  – Type: pdflink
Text:
  Availability: 0
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 11773180
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Neuroendocrine predictors of response to intravenous clomipramine therapy for refractory obsessive–compulsive disorder <FNR></FNR><FN>Presented in part at the 2000 APA meeting May, Chicago, Illinois, Young Investigators Poster, and the 2001 ADAA Conference in Atlanta, Georgia </FN>
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Mathew%2C+Sanjay+J%2E%22">Mathew, Sanjay J.</searchLink><br /><searchLink fieldCode="AR" term="%22Coplan%2C+Jeremy+D%2E%22">Coplan, Jeremy D.</searchLink><br /><searchLink fieldCode="AR" term="%22Perko%2C+Kathryn+A%2E%22">Perko, Kathryn A.</searchLink><br /><searchLink fieldCode="AR" term="%22Goetz%2C+Raymond+R%2E%22">Goetz, Raymond R.</searchLink><br /><searchLink fieldCode="AR" term="%22De+la+Neuz%2C+Manuel%22">De la Neuz, Manuel</searchLink><br /><searchLink fieldCode="AR" term="%22Hollander%2C+Eric%22">Hollander, Eric</searchLink><br /><searchLink fieldCode="AR" term="%22Liebowitz%2C+Michael+R%2E%22">Liebowitz, Michael R.</searchLink><br /><searchLink fieldCode="AR" term="%22Fallon%2C+Brian+A%2E%22">Fallon, Brian A.</searchLink><br /><searchLink fieldCode="AR" term="%22Mathew%2C+S+J%22">Mathew, S J</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Coplan%2C+J+D%22">Coplan, J D</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Perko%2C+K+A%22">Perko, K A</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Goetz%2C+R+R%22">Goetz, R R</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22de+la+Neuz%2C+M%22">de la Neuz, M</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Hollander%2C+E%22">Hollander, E</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Liebowitz%2C+M+R%22">Liebowitz, M R</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Fallon%2C+B+A%22">Fallon, B A</searchLink> (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Depression+%26+Anxiety+%281091-4269%29%22">Depression & Anxiety (1091-4269)</searchLink>. 2001, Vol. 14 Issue 4, p199-208. 10p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Therapeutics%22">Therapeutics</searchLink><br /><searchLink fieldCode="DE" term="%22Obsessive-compulsive+disorder%22">Obsessive-compulsive disorder</searchLink><br /><searchLink fieldCode="DE" term="%22Neuroses%22">Neuroses</searchLink><br /><searchLink fieldCode="DE" term="%22Pharmacology%22">Pharmacology</searchLink><br /><searchLink fieldCode="DE" term="%22Neuroendocrinology%22">Neuroendocrinology</searchLink><br /><searchLink fieldCode="DE" term="%22Diagnosis+of+obsessive-compulsive+disorder%22">Diagnosis of obsessive-compulsive disorder</searchLink><br /><searchLink fieldCode="DE" term="%22Evaluation+research%22">Evaluation research</searchLink><br /><searchLink fieldCode="DE" term="%22Research+funding%22">Research funding</searchLink><br /><searchLink fieldCode="DE" term="%22Blind+experiment%22">Blind experiment</searchLink><br /><searchLink fieldCode="DE" term="%22Drug+administration%22">Drug administration</searchLink><br /><searchLink fieldCode="DE" term="%22Hydrocortisone%22">Hydrocortisone</searchLink><br /><searchLink fieldCode="DE" term="%22Clomipramine%22">Clomipramine</searchLink><br /><searchLink fieldCode="DE" term="%22Treatment+effectiveness%22">Treatment effectiveness</searchLink><br /><searchLink fieldCode="DE" term="%22Oral+drug+administration%22">Oral drug administration</searchLink><br /><searchLink fieldCode="DE" term="%22Prolactin%22">Prolactin</searchLink><br /><searchLink fieldCode="DE" term="%22Intravenous+therapy%22">Intravenous therapy</searchLink><br /><searchLink fieldCode="DE" term="%22Dose-effect+relationship+in+pharmacology%22">Dose-effect relationship in pharmacology</searchLink><br /><searchLink fieldCode="DE" term="%22Research+methodology%22">Research methodology</searchLink><br /><searchLink fieldCode="DE" term="%22Research%22">Research</searchLink><br /><searchLink fieldCode="DE" term="%22Treatment+failure%22">Treatment failure</searchLink><br /><searchLink fieldCode="DE" term="%22Comparative+studies%22">Comparative studies</searchLink><br /><searchLink fieldCode="DE" term="%22Human+growth+hormone%22">Human growth hormone</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: The current study examines the neuroendocrine response to intravenous clomipramine (IV CMI) in oral CMI-resistant obsessive-compulsive disorder (OCD) patients on day 1 and day 14 of treatment to identify predictors of response. Forty-four OCD patients with an inadequate response or poorly tolerant to oral CMI were begun at 25 mg IV CMI, increasing to 250 mg by day 10, and continuing on that dose to day 14. On day 1, plasma levels of prolactin (PRL), growth hormone (GH), and cortisol were obtained immediately before the 25 mg IV infusion, and at five 30-minute time points after the infusion. On day 14, hormonal samples were obtained in a similar fashion. Response was assessed by the Clinical Global Impressions (CGI). Low PRL(MAX) to IV CMI and low cortisol levels overall on day 1 were both significantly associated with clinical response at day 14. An overall increase in growth hormone (GH) secretion during the day 14 testing was associated with positive response. A pronounced PRL response to IV CMI on day 14 was exhibited by the nonresponders, whereas a smaller and later but significant increase in PRL was noted in the responders. The findings suggest that in this sample of oral CMI-resistant patients with OCD, neuroendocrine measures derived from pharmacological challenge with IV CMI are capable of distinguishing IV CMI treatment responders from nonresponders. The limitations of IV CMI as a specific probe of serotonin function are discussed. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Depression & Anxiety (1091-4269) is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=11773180
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1002/da.1067
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 10
        StartPage: 199
    Subjects:
      – SubjectFull: Therapeutics
        Type: general
      – SubjectFull: Obsessive-compulsive disorder
        Type: general
      – SubjectFull: Neuroses
        Type: general
      – SubjectFull: Pharmacology
        Type: general
      – SubjectFull: Neuroendocrinology
        Type: general
      – SubjectFull: Diagnosis of obsessive-compulsive disorder
        Type: general
      – SubjectFull: Evaluation research
        Type: general
      – SubjectFull: Research funding
        Type: general
      – SubjectFull: Blind experiment
        Type: general
      – SubjectFull: Drug administration
        Type: general
      – SubjectFull: Hydrocortisone
        Type: general
      – SubjectFull: Clomipramine
        Type: general
      – SubjectFull: Treatment effectiveness
        Type: general
      – SubjectFull: Oral drug administration
        Type: general
      – SubjectFull: Prolactin
        Type: general
      – SubjectFull: Intravenous therapy
        Type: general
      – SubjectFull: Dose-effect relationship in pharmacology
        Type: general
      – SubjectFull: Research methodology
        Type: general
      – SubjectFull: Research
        Type: general
      – SubjectFull: Treatment failure
        Type: general
      – SubjectFull: Comparative studies
        Type: general
      – SubjectFull: Human growth hormone
        Type: general
    Titles:
      – TitleFull: Neuroendocrine predictors of response to intravenous clomipramine therapy for refractory obsessive–compulsive disorder <FNR></FNR><FN>Presented in part at the 2000 APA meeting May, Chicago, Illinois, Young Investigators Poster, and the 2001 ADAA Conference in Atlanta, Georgia </FN>
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Mathew, Sanjay J.
      – PersonEntity:
          Name:
            NameFull: Coplan, Jeremy D.
      – PersonEntity:
          Name:
            NameFull: Perko, Kathryn A.
      – PersonEntity:
          Name:
            NameFull: Goetz, Raymond R.
      – PersonEntity:
          Name:
            NameFull: De la Neuz, Manuel
      – PersonEntity:
          Name:
            NameFull: Hollander, Eric
      – PersonEntity:
          Name:
            NameFull: Liebowitz, Michael R.
      – PersonEntity:
          Name:
            NameFull: Fallon, Brian A.
      – PersonEntity:
          Name:
            NameFull: Mathew, S J
      – PersonEntity:
          Name:
            NameFull: Coplan, J D
      – PersonEntity:
          Name:
            NameFull: Perko, K A
      – PersonEntity:
          Name:
            NameFull: Goetz, R R
      – PersonEntity:
          Name:
            NameFull: de la Neuz, M
      – PersonEntity:
          Name:
            NameFull: Hollander, E
      – PersonEntity:
          Name:
            NameFull: Liebowitz, M R
      – PersonEntity:
          Name:
            NameFull: Fallon, B A
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 12
              Text: 2001
              Type: published
              Y: 2001
          Identifiers:
            – Type: issn-print
              Value: 10914269
          Numbering:
            – Type: volume
              Value: 14
            – Type: issue
              Value: 4
          Titles:
            – TitleFull: Depression & Anxiety (1091-4269)
              Type: main
ResultId 1